Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

2.5K
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
2.5K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

541
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
541
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

730
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
730
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

790
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
790
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Angina IV: Management01:26

Angina IV: Management

372
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
372

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Collaborative neurocardiology board meetings for decision-making in stroke care: a real-world experience.

Neurological research and practice·2026
Same author

Collaborative neurocardiology board meetings for decision-making in stroke care: a real-world experience.

Neurological research and practice·2026
Same author

Editorial: Current proceedings in magnetocardiology-past, present, future.

Frontiers in cardiovascular medicine·2024
Same author

Magnetocardiography at rest predicts cardiac death in patients with acute chest pain.

Frontiers in cardiovascular medicine·2023
Same author

Medical graphics to improve patient understanding and anxiety in elderly and cognitively impaired patients scheduled for transcatheter aortic valve implantation (TAVI).

Clinical research in cardiology : official journal of the German Cardiac Society·2023
Same author

High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany.

Clinical research in cardiology : official journal of the German Cardiac Society·2023

Related Experiment Video

Updated: Mar 12, 2026

Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test
06:35

Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test

Published on: April 27, 2016

18.9K

[ECS guidelines 2016 - dyslipidaemias].

D Sinning1, U Landmesser2,3,4

  • 1Klinik für Kardiologie, Charité - Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Deutschland.

Herz
|November 16, 2016
PubMed
Summary
This summary is machine-generated.

New guidelines emphasize treating dyslipidemia by targeting low-density lipoprotein (LDL) cholesterol, especially for high-risk patients. High-density lipoprotein (HDL) cholesterol is not a recommended treatment target.

Keywords:
DyslipidaemiaEzetimibeLow-density lipoprotein cholesterolProprotein convertase subtilisin/kexin type 9Statin

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.9K

Related Experiment Videos

Last Updated: Mar 12, 2026

Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test
06:35

Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test

Published on: April 27, 2016

18.9K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.9K

Area of Science:

  • Cardiology
  • Atherosclerosis
  • Lipid Metabolism

Background:

  • Dyslipidemia is a primary driver of atherosclerotic cardiovascular disease, leading to severe complications like heart attacks and strokes.
  • Recent European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) guidelines update dyslipidemia management strategies.

Purpose of the Study:

  • To summarize the updated 2016 ESC/EAS guidelines for dyslipidemia management.
  • To highlight the reinforced emphasis on risk-based low-density lipoprotein (LDL) cholesterol targets.

Main Methods:

  • Review of the 2016 ESC/EAS joint guidelines on dyslipidemia management.
  • Analysis of recommendations for LDL cholesterol targets and therapeutic interventions.

Main Results:

  • LDL cholesterol is confirmed as the primary treatment target; HDL cholesterol is not recommended as a target.
  • Specific LDL targets are set: <70 mg/dl for very high-risk patients, and >50% reduction for specific high-risk groups.
  • Statins are first-line therapy, with increased use of maximum tolerated doses recommended.

Conclusions:

  • The guidelines advocate for intensified LDL cholesterol lowering, particularly with statins, ezetimibe, and PCSK9 inhibitors for high-risk individuals.
  • PCSK9 inhibitors are indicated for familial hypercholesterolemia and very high-risk patients with persistent high LDL despite other therapies.